SinoMab BioScience Limited
HKEX:3681.HK
1.19 (HKD) • At close November 12, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | SinoMab BioScience Limited |
Symbool | 3681.HK |
Munteenheid | HKD |
Prijs | 1.19 |
Beurswaarde | 1,286,014,555 |
Dividendpercentage | 0% |
52-weken bereik | 1.07 - 1.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Shui On Leung |
Website | https://www.sinomab.com |
An error occurred while fetching data.
Over SinoMab BioScience Limited
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA),
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)